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Onco-nephrology is a rapidly growing field that has recently garnered significant attention. Although the risk of
developing cancer is reported to be higher in patients with end-stage renal disease (ESRD) than in the general
population, the screening protocol and the treatment of cancer in ESRD patients have not yet been established.
Recent studies have suggested that cancer screening in dialysis patients would be ineffective from a cost and
survival benefit perspective. Nevertheless, the ESRD population is heterogeneous, including patients of varying age
and comorbidity, and it is essential to identify those who would benefit from cancer screening. Once patients with
ESRD are diagnosed with cancer, anti-cancer treatment should be initiated. However, a treatment strategy has not
yet been established. Although many drugs require dose adjustments in hemodialysis patients, data on the
pharmacokinetics of anti-cancer agents in these patients remain scarce. This review addresses the recent evidence
of cancer risk and screening in the ESRD population and the pharmacokinetics of anti-cancer agents in
hemodialysis patients.
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Onco-nephrology is a new and evolving subspecialty that
connects two different areas, oncology and nephrology.
Improvement in cancer therapies has led to an increase
in the number of cancer survivors, some of whom de-
velop acute and chronic kidney complications. A better
understanding of cancer-associated kidney complica-
tions, such as paraneoplastic glomerulopathies and
chemotherapy-associated kidney diseases, is thus re-
quired to enable oncologists and nephrologists to treat
patients suffering from cancer and kidney disease [1–3].
The term “onco-nephrology” usually relates to acute and
chronic kidney complications that arise due to cancer or
cancer treatment. In order to provide evidence-based
care for patients with cancer and kidney disease, how-
ever, the issues on how to manage cancer in patients
with end-stage renal disease (ESRD) should be incorpo-
rated into the field of onco-nephrology. As discussed* Correspondence: motoy@kuhp.kyoto-u.ac.jp
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field (Table 1).
The first issue relates to cancer screening in patients
with ESRD. Since patients with ESRD are at a higher risk
of cancer than the general population [4, 5], there is an
urgent need to establish cancer-screening protocols for
patients with ESRD. Previous studies have failed to dem-
onstrate a substantial increase in life expectancy from
cancer screening in patients with ESRD [6, 7]. These
studies reported that this conclusion should be tempered
when cancer screening is applied to individual patients,
however, since the ESRD population is heterogeneous,
and includes patients who are expected to have a long
life expectancy as well as patients with a limited life ex-
pectancy as a result of advanced age or severe comorbid-
ities. In order to establish ways to identify individuals
who should receive cancer screening in this population,
the frequency of cancer, the cost and effectiveness of
screening tests, and patient life expectancy all need to be
taken into consideration.
The second issue is that it is essential to establish treat-
ment recommendations for ESRD patients diagnosed withdistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Table 1 Areas of special importance in the field of onco-nephrology
Areas Comments
The representative areas in (A)~(C) can be described as follows (the details were reviewed previously [1]).
(A) Acute kidney injury in cancer
patients
The causes of AKI in cancer patients can be categorized as prerenal, intrinsic, and postrenal.
• Prerenal (extracellular fluid depletion, hypercalcemia, hepatic sinusoidal occlusive syndrome, drugs)
• Intrinsic (acute tubular necrosis, lymphomatous infiltration of the kidney, cast nephropathy, tumor lysis
syndrome, thrombotic microangiopathy, secondary glomerulopathies)
• Postrenal (extrarenal obstruction due to primary disease, retroperitoneal lymphadenopathy,
retroperitoneal fibrosis)
(B) Paraneoplastic glomerulopathies • Solid malignancy-associated membranous nephropathy
• Hematologic malignancy-associated minimal change disease
(C) Chemotherapy-associated kidney
manifestations
• Minimal change disease and focal segmental glomerulosclerosis (interferon, pamidronate)
• Acute tubular necrosis and electrolyte wasting (cisplatin)
• Magnesium wasting (cetuximab)
• Thrombotic microangiopathy (bevacizumab, tyrosine kinase inhibitors, and gemcitabine)
• Cast nephropathy (methotrexate)
(D) Cancer risk and screening in
patients with ESRD
Although the etiologies of cancer-associated renal diseases in (A)~(C) are relatively well understood, the proto-
cols of the cancer screening and effective anti-cancer treatment for ESRD patients are not established yet.
(E) Anti-cancer chemotherapy in
patients with ESRD
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likelihood that cancer patients will receive optimal anti-
cancer therapy and supportive care. Chemotherapy might
be withheld because they are undergoing hemodialysis
(HD). A lack of information concerning chemotherapy in
patients with ESRD also leads to the improper use of anti-
cancer agents and severe adverse effects in these patients
[8]. Data on renal or dialysis clearance for these agents re-
main scarce, although the number of case studies that in-
clude pharmacokinetic data and information related to the
safety and efficacy of these agents has gradually increased
in recent years. It is essential to find dose adjustment
models and to modify existing chemotherapy protocols
adequately for HD patients.
This review updates the information on cancer screen-
ing and the pharmacokinetics of anti-cancer agents in
patients with ESRD.
Cancer risk in patients with ESRD
Observational studies have suggested an increased can-
cer risk in patients with ESRD [9, 10]. Patients on
chronic dialysis have an increased risk of cancer for sev-
eral reasons, including the presence of chronic infection,
a compromised immune system, nutritional deficiencies,
and altered DNA repair [5]. There are also predisposing
factors that contribute to the higher incidence of certain
cancers in dialysis patients. Acquired renal cystic kidney
disease increases the risk of renal cell carcinoma [11].
Long-term use of analgesics is a risk factor for transi-
tional cell carcinoma of the bladder, ureter, and renal
pelvis and for renal cell carcinoma [11–13]. In addition,the use of prolonged oral cyclophosphamide is a risk fac-
tor for bladder cancer [14]. Notably, there is an in-
creased risk of several infection-associated cancers, such
as the liver, cervix uteri, and tongue [5, 15–17]. The
higher prevalence of infection with hepatitis B and C
and human papillomavirus in HD patients probably ac-
counts for the increased risks of these cancers [18–20].
In contrast, it remains controversial whether the risk of
cancer of the lung, stomach, colon, breast, and corpus
uteri is increased in patients with ESRD [5, 15–17]. In
Japan, the most common cancer in ESRD patients is
renal cell carcinoma, and the second is multiple mye-
loma, followed by liver and colon cancer in males and
uterine cancer in females [21]. In contrast, while the
most common cancer in ESRD patients in the USA is
renal cell carcinoma as is in Japan, the second is prostate
cancer in males and breast cancer in females [22]. In
addition, whether cancer risk differs between transplant
periods (under immunosuppression) and periods of dia-
lysis after transplant failure (when immunosuppression
is ceased or reduced) was investigated in a retrospective
cohort of 8173 kidney transplant recipients [23]. In the
multivariate analysis, incidences of non-Hodgkin lymph-
oma, lip cancer, and melanoma, which were included in
infection- or immune-related cancers, were lower during
dialysis after transplant failure whereas the incidence of
thyroid cancer, which was shown to be included in
ESRD-related cancer, was lower during periods of trans-
plant function. More recently, a larger retrospective study
including 202,195 kidney transplant candidates and recipi-
ents also examined whether cancer risk changes between
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large sample size, this study provided more precise esti-
mates of many individual cancers. In this study, individ-
uals with transplants had higher adjusted risks of Kaposi
sarcoma; non-Hodgkin lymphoma; Hodgkin lymphoma;
melanoma; and cervical, anal, vaginal/vulvar, penile, oto-
pharyngeal, liver, stomach, lung, lip, and non-epithelial
skin cancers (which were included in infection- or
immune-related cancers) than those with nonfunctioning
kidneys on waiting lists and those with graft failure. In
contrast, individuals with nonfunctioning kidneys had
higher adjusted risks of kidney and thyroid cancers, which
were considered to be related to ESRD. These studies in-
dicated that the risk of infection- or immune-related can-
cers was higher in transplant recipients with functioning
kidneys whereas the risk of ESRD-related cancers was
higher in those under dialysis following kidney failure.
Cancer screening in the ESRD population
Standard malignancy-screening recommendations are
based on the assumption that those screened would have
a normal life span. It must be taken into consideration
that benefit may be reduced or absent in individuals with
low life expectancy. There is a general agreement that
routine cancer screening is unlikely to result in a net
benefit for individuals with limited life expectancy [24,
25]. This is reflected in the existing guidelines for vari-
ous kinds of cancer, although different guidelines recom-
mend different life expectancies or age cutoffs for
cessation of cancer screening [26]. In the ESRD popula-
tion, the expected remaining lifetime of most dialysis
patients is shorter than the time lived after a cancer
diagnosis, making cancer screening ineffective in terms
of cost and survival benefit [27, 28]. In a cost-
effectiveness analysis that compared cancer screening in
patients on HD with screening in the general population,
the screening benefits of mammography, Papanicolaou
tests, flexible sigmoidoscopy, and serum prostate-
specific antigen (PSA) levels were denied for the fol-
lowing reasons [6]: First, the costs per unit of survival
benefit conferred by cancer screening were 1.6 to
19.3 times higher in patients with ESRD compared
with those in the general population. Second, the net
gain of life expectancy in patients with ESRD via
these screening programs was calculated to be 5 days
or less. Based on these results, it was concluded that
routine cancer screening in the ESRD population was
a relatively ineffective allocation of financial resources.
Similar findings were also shown in a study evaluating
the efficacy of breast and cervical cancer screening of
Canadian women on HD [7].
It is important to recognize that the results obtained
in these studies are average results for the ESRD popula-
tion. It must not be concluded that no HD patients needcancer screening. Life expectancy for patients on dialysis
would be better in the absence of coexisting complica-
tions, for example. In addition, malignancy is a common
cause of death in patients receiving dialysis. In Japan, the
percentage of HD patients who died of malignancies was
9.1 % in total causes of death, ranking third after cardiac
failure (27.2 %) and infectious diseases (20.3 %) [29]. It
should also be noted that patient survival in Japan has
been better than that in the Western countries [30]. In
addition, the magnitude of the association between mor-
tality and cancer was greater in Japan than in Europe or
the USA [30]. One cannot ignore the significant benefit
to a patient who is diagnosed with a malignancy at an
early stage by cancer screening and who could poten-
tially receive curative therapy. These screening tests
seem to be better limited to individualized patients with
risk factors for malignancy and long life expectancy. The
difference in cancer incidence between kidney transplant
recipients and dialysis patients with nonfunctioning kid-
neys also suggests a need to individualize cancer screen-
ing [22, 23]. In the CANcer and DialYsis (CANDY)
study including 178 patients on chronic HD who subse-
quently had cancer, the mean and median times for can-
cer development after dialysis initiation were 30.8 and
13 months, respectively [8]. These results may indicate
that cancer screening should be performed not long after
the beginning of dialysis sessions, especially within the
first few years. Further studies would help to establish
cancer-screening protocols.
Although cancer-screening protocols in patients with
ESRD have not been established, the efficacy of tumor
markers has been relatively well examined in the ESRD
population. Tumor markers have been used to follow
the clinical course of certain cancers and also used as
cancer-screening tools (Table 2). Since many tumor
markers are not removed effectively by HD due to the
relatively high molecular weight, serum levels are ele-
vated after HD as a result of hemoconcentration, limit-
ing their clinical effectiveness [31–33]. Total PSA, the
sum of free and complex PSA, is used as a screening test
for prostate cancer, usually in combination with digital
rectal and ultrasound-guided examination. The percent
of free PSA (fPSA) in total PSA (tPSA) is also used to
enhance the discrimination of prostate cancer because
the percent of fPSA is lower in men with prostate cancer
than that in men with benign disorders [34]. tPSA is
valid in dialysis patients, although fPSA is elevated and
should not be used as a screening test for prostate can-
cer in dialysis patients [35]. Cancer antigen 125 (CA-
125) is a tumor marker for ovarian cancer but is also
produced by mesothelial cells [36]. Serum CA-125 levels
are elevated in HD patients with serosal fluid, pleural ef-
fusion, ascites, etc., and the results should be interpreted
with caution [37]. In particular, this marker is a less
Table 2 Summary of tumor markers in dialysis patients (modified from [31])
Tumor marker Comments
(A) Reliable in dialysis patients
Total prostate-specific antigen (tPSA) Free PSA (fPSA) could be filtered through glomeruli, consistent with its low
molecular weight (28 kDa). Decreased GFR leads to an increased serum
level of fPSA and higher percent fPSA to tPSA (%fPSA), since the level of
tPSA does not differ compared with that of the controls [35]. Although not
eliminated by low-flux membranes, fPSA is cleared by high-flux mem-
branes [76], since molecules smaller than 5 and 50 kDa are filtered by low-
flux and high-flux dialysis membranes, respectively [39].
β-human chorionic gonadotropin (β-hCG), α-fetoprotein
(B) Falsely elevated in dialysis patients
Cancer antigen 125 (CA-125) CA-125 is elevated in patients with peritoneal, pleural, or pericardial
effusion [37]. In particular, CA-125 is falsely elevated as a result of nonspe-
cific peritoneal irritation or peritonitis in patients undergoing peritoneal
dialysis [38]. The serum concentration of CA-125 is increased during
hemodialysis, probably due to hemoconcentration [32].
Carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA),
squamous cell carcinoma (SCC) antigen, and neuron-specific enolase
(NSE)
Although the metabolism and clearance are not fully understood, previous
studies revealed that the serum levels of CA19-9, CEA, SCC, and NSE are
elevated in dialysis patients compared with patients with normal renal
function [39–42]. An increase in the serum levels of these tumor markers is
also found during hemodialysis, probably as a result of hemoconcentration
[32]. It should be noted that SCC is cleared by high-flux membranes due
to its molecular weight of 42 to 48 kDa, although it is not eliminated by
low-flux membranes [33].
GFR glomerular filtration rate
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going peritoneal dialysis, since serum levels may be
falsely elevated as a result of nonspecific peritoneal irri-
tation or peritonitis [38]. Carbohydrate antigen 19-9
(CA19-9), carcinoembryonic antigen (CEA), squamous
cell carcinoma (SCC) antigen, and neuron-specific eno-
lase (NSE) have also been reported to be falsely elevated
in dialysis patients compared with patients with normal
renal function [39–42]. In contrast, α-fetoprotein and
β-human chorionic gonadotropin are reliable tumor
markers in dialysis patients [43].
Although increased risks of colorectal and breast can-
cer have not been established in the ESRD population,
as stated above, it has been emphasized that the results
of fecal occult blood tests and mammography in patients
with ESRD should be interpreted with caution. A
positive stool guaiac test occurs at a higher frequency in
dialysis patients due to an increased incidence of non-
malignant gastrointestinal abnormalities. In one series,
the incidence of guaiac positive stools was three times
higher in asymptomatic dialysis patients compared with
non-ESRD controls [44]. However, the presence of a
positive stool test in asymptomatic patients may enable
the early detection of colorectal cancer. Mammography,
a low-dose x-ray system for examination of the breasts,
aids in the earlier detection of breast cancer. The pres-
ence of benign vascular calcification in women with
ESRD complicates mammography and leads to higher
rates of false-positive results [45]. Since these cancers do
not appear to be more common in patients with ESRD,patients on transplant waiting lists and patients with
predisposing risk factors and long expected survival
would be appropriate candidates for these screenings.
Pharmacokinetics of anti-cancer agents in patients
on hemodialysis
Chemotherapy can be challenging when the patient’s
renal function is compromised. Although most anti-
cancer agents are eliminated through the kidney, data on
renal or dialysis clearance of these agents are scarce and
often incomplete. The available recommendations for
the appropriate dose adjustment of these agents for the
ESRD population are based on data from a small series
of case reports and expert opinions [46]. Many cytotoxic
agents are excreted predominantly in the urine un-
changed or as active/toxic metabolites. Thus, any reduc-
tion in renal clearance may result in the accumulation of
potentially toxic components and overdose. For anuric
HD patients, although the renal toxicity of chemothera-
peutic agents is not a problem, the patients are exposed
to all other potential dose-related systemic adverse ef-
fects. In addition, previous pharmacokinetic studies indi-
cated that changes in the non-renal drug clearance
occur in patients with ESRD [47]. Drug-metabolizing en-
zymes and transporters in other organs are considered
to be affected by kidney diseases [47]. The influence of
renal insufficiency on the renal and non-renal drug
clearance of anti-cancer agents remains incompletely
understood. The CANDY study included 178 patients on
chronic HD who subsequently had cancer and 50
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ment. Most of the patients received at least one anti-
cancer agent for which specific attention was required in
terms of drug dosage adjustments (72 %) and adequate
timing of administration (82 %) [8]. A total of 44 % of
the treated patients developed iatrogenic toxicity: 34 %
related to drugs requiring dosage adjustment and 17 %
related to additional drugs with no existing management
recommendations in dialysis patients. These results indi-
cated that the lack of evidence concerning the use of
systemic anti-cancer agents in renal insufficiency could
lead to the inappropriate use of chemotherapy and fatal
toxic effects in these patients. Although the pharmaco-
kinetics of several chemotherapeutic agents in HD pa-
tients has been relatively well examined in case studies,
the dose and timing of administration remain under de-
bate. Previous case studies have examined different
doses and intervals between HD and drug administra-
tion. HD immediately after dialyzable drug administra-
tion may improve tolerance although such protocols
may lead to the reduction of anti-neoplastic efficacy and
impose excess burden on the patient and treatment
teams. In addition, a limited number of facilities can
offer both HD and anti-cancer treatment on the same
day. These limitations might deprive the patient of op-
portunities to receive optimal anti-cancer treatment.
These social factors must also be taken into consider-
ation in the establishment of anti-cancer therapeutic
protocols.
This section focuses on the relatively well-described
anti-cancer agents used in HD patients that have differ-
ent main elimination organs, carboplatin (mainly elimi-
nated by the kidney) and 5-fluorouracil (5-FU) (mainly
eliminated by the liver), as well as tyrosine kinase inhibi-
tors, that are frequently used in this new era of targeted
anti-cancer therapy.
Carboplatin
One of the most widely used anti-cancer agents in HD
patients is a platinum derivative, carboplatin [48, 49]. In
patients with normal renal function, approximately 70 %
of the administered dose is excreted in the urine [50]. It
has been shown that the target area under the curve
(AUC) of carboplatin is associated with myelosuppres-
sive and cytotoxic effects. Therefore, in clinical practice,
the Calvert formula is well accepted for calculating the
dose of carboplatin: dose (mg) = AUC (mg/ml × min) ×
(glomerular filtration rate [GFR] (ml/min) + 25) [50]. For
patients with ESRD, many clinicians still use this for-
mula with the assumption that the GFR can be almost
equal to zero [51–53]. This AUC-targeted dose adjust-
ment has permitted the individualization of the carbo-
platin dose for maximum effect with tolerable adverse
effects. The HD setting after the administration ofcarboplatin influences the concentration of carboplatin
in the plasma, since carboplatin can be removed from
the plasma by HD [48]. The interval between the admin-
istration of carboplatin and HD varied between 1 and
24 h in previous studies (Table 3). In these studies, the
AUCs varied depending on the doses and intervals be-
tween drug infusion and HD. Although there were varia-
tions between studies, the AUCs seemed to be higher
when HD was started long after carboplatin infusion. A
certain amount of carboplatin can be eliminated by per-
forming HD in an early phase when the protein binding
ratio is low [54]. This dialyzability may help to improve
tolerance, although actual AUC values may be less reli-
able and more unstable when HD is performed immedi-
ately after the administration [51]. The protein binding
of carboplatin, which hinders its elimination in HD, has
been observed to increase by 50 % after 24 h of adminis-
tration [54]. Oguri et al. reported that the actual AUC
values were approximately 20 % higher than the target
AUC when HD was performed 24 h after the adminis-
tration of carboplatin [51]. Particular attention should be
paid to the development of adverse events such as
hematological toxicities when there is a long interval be-
tween carboplatin administration and HD.
5-FU
5-FU is mainly metabolized via redihydropyrimidine de-
hydrogenase in the liver and other tissues, and only a
small amount of 5-FU (approximately 10 % of the ad-
ministered dose) is eliminated unchanged by the kidney
[55]. In line with its short elimination half-life (20 min),
5-FU is given by intravenous continuous infusion over
several days as well as by intravenous bolus infusion,
allowing the easy determination of systemic clearance
based on steady-state plasma concentrations [56]. In a
previous case report, a weekly regimen composed of
CPT-11 (50 mg/m2) followed by leucovorin (10 mg/m2)
and 5-FU (400 mg/m2) was administered immediately
after HD. Although the dose of 400 mg/m2 5-FU was re-
duced compared with that of patients with normal renal
function, the bolus intravenous injection of 5-FU to HD
patients after HD sessions provided a blood concentra-
tion profile similar to that in normal subjects [57]. The
patient presented with grade 3 hematological toxicity
that was recovered by granulocyte colony-stimulating
factor. In another study, the intravenous bolus and con-
tinuous infusion of 5-FU was included in the FOLFOX 4
regimen; the doses of oxaliplatin and 5-FU were both re-
duced from those in the original FOLFOX 4 regimen.
The dose of oxaliplatin was 40 mg/m2, and 5-FU was
given as a bolus of 300 mg/m2 followed by a continuous
intravenous infusion of 500 mg/m2 [58]. HD was per-
formed 1 h after the administration of oxaliplatin on day
1 and was repeated 2 days later after the completion of
Table 3 Intervals between carboplatin infusion and HD and AUCs of free carboplatin in previous studies of carboplatin-based
chemotherapy in HD patients






(A) Hemodialysis was initiated soon after carboplatin infusion (1~2 h after infusion).
Kurata et al. (1994) [77] 1 Ovarian carcinoma 240 mg/m2 (cycle 1) 1 3.14
240 mg/m2 (cycle 2) 2 5.09
Suzuki et al. (1997) [78] 1 Merkel cell carcinoma 150 mg (cycle 1) 1 4.6
150 mg (cycle 2) 2 4.8
Watanabe et al. (2002) [52] 1 Ovarian carcinoma 125 mg (cycle 1) 1.5 2.21
Furuya et al. (2003) [79] 1 Urothelial carcinoma 125 mg 1 2.44
Takezawa et al. (2008) [80] 1 SCLC 250 mg/m2 (cycle 1) 1 4.10
275 mg/m2 (cycle 2) 1 4.16
Kamata et al. (2009) [81] 1 NSCLC 150 mg/m2 1 4.9
Yoshida et al. (2009) [82] 1 Ovarian carcinoma 125 mg 1 0.98
Kondo et al. (2012) [83] 1 Cancer of unknown primary 125 mg (cycle 1) 1 3.03
125 mg (cycle 2) 1 3.44
125 mg (cycle 3) 1 3.5
Hiraike et al. (2012) [54] 1 SCLC 480 mg (cycle 1) 1 13.45
170 mg (cycle 2) 1 5.74
(B) Hemodialysis was initiated long after carboplatin infusion (16~24 h after infusion).
Motzer et al. (1990) [84] 2 Germ cell tumor 100 mg/m2 24 6.7
Germ cell tumor 100 mg/m2 24 6.9
Chatelut et al. (1994) [48] 1 Ovarian carcinoma 100 mg (cycle 1) 24 3.5
150 mg (cycle 2) 24 6.7
150 mg (cycle 3) 24 6.06
Watanabe et al. (2002) [52] 1 Ovarian carcinoma 125 mg (cycle 2) 16 4.43
125 mg (cycle 3) 16 4.75
125 mg (cycle 4) 16 4.13
Yokoyama et al. (2006) [85] 1 Ovarian carcinoma 200 mg (cycle 1) 24 8.03
200 mg (cycle 2) 16 5.69
Oguri et al. (2010) [51] 2 NSCLC 100 mg 24 4.7
Ovarian cancer 125 mg 24 6.1
Kodama et al. (2010) [86] 1 Ovarian carcinoma 100 mg (cycle 1) 24 3.48
150 mg (cycle 2) 24 4.23
175 mg (cycle 3) 24 5.55
150 mg (cycle 4) 24 4.59
SCLC small cell lung cancer, NSCLC non-small cell lung cancer
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leukopenia (both grade 3) were observed after the first
treatment. A total of four courses were administered
thereafter by reducing the dose of oxaliplatin to 32 mg/
m2, the intravenous bolus of 5-FU to 240 mg/m2, and
the continuous infusion of 5-FU to 400 mg/m2. After
the dose reduction, no adverse events were observed
other than anorexia (grade 1). Although the dosereduction of 5-FU was not recommended in previous
studies [46, 59, 60], these studies indicated that a further
accumulation of cases is needed to establish the optimal
dose in HD patients. Particular attention should also be
paid to the development of 5-FU-induced encephalop-
athy, especially when a higher dose of 5-FU is adminis-
tered. Ammonia, a metabolite of 5-FU, accumulates in
large amounts after the administration of high-dose 5-
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factor of hyperammonemia related to 5-FU infusion [63,
64]. It has been suggested that a large amount of fluor-
oacetate, a final metabolite of 5-FU, could be accumu-
lated in patients with renal dysfunction and inhibit the
Krebs cycle. This could cause impairment in the ATP-
dependent urea cycle, resulting in lactic acidosis and
further exacerbation of a hyperammonemic state [62,
64]. The direct toxicity of alpha-fluoro-beta-alanine
(FBAL), an intermediate metabolite of 5-FU, on myelin
was also proposed as the cause of 5-FU-induced enceph-
alopathy [65]. In HD patients, FBAL, which is mainly ex-
creted by the kidney with minor elimination via bile and
the bowel, was reported to accumulate approximately
twofold higher than expected in patients with normal
renal function [66]. The authors also reported that FBAL
could be eliminated by HD, suggesting that more inten-
sive dialysis treatment may be useful for improving the
elimination of FBAL to minimize the possible risks of
FBAL-mediated toxicity.
Tyrosine kinase inhibitors
Several studies have recently examined the pharmaco-
kinetics of tyrosine kinase inhibitors such as sunitinib,
imatinib, sorafenib, and erlotinib in HD patients [67–
71]. After oral administration, these agents are primarily
metabolized in the liver by cytochrome CYP3A4, with
only a small proportion excreted in the urine [72, 73].
These agents were reported to be minimally affected by
HD [67, 69–71]. Therefore, administration can take
place anytime, independent of the HD sessions. Previous
studies have shown that treatment with these agents is
well tolerated and has good efficacy in patients with
ESRD [71, 72, 74, 75]. However, one study showed that
dose reduction or discontinuation of sorafenib was
frequently needed (even with lower concentrations of so-
rafenib) in patients with metastatic renal cell carcinoma
undergoing HD [70]. Serious adverse events were found
in 9 of 10 patients, including a grade 5 subarachnoid
hemorrhage and a grade 4 cerebellar hemorrhage. The
authors suggested that the patients on chronic HD
might be susceptible to the unfavorable effects of anti-
angiogenic agents like sorafenib due to their vulnerable
vascular tissues. Treatment of HD patients with tyrosine
kinase inhibitors appears to be feasible, but special
attention should be paid to the occurrence of serious
adverse events, considering the underlying risk factors of
HD patients.
Conclusions
Since a growing number of patients with ESRD are
developing cancer, it is essential to establish evidence-
based recommendations for cancer screening and anti-
cancer treatment in the ESRD population. This reviewprovided recent evidence for cancer risk and screening
in the ESRD population. There is a pressing need for
clinical trials that are designed to identify those who
would benefit from cancer screening in this population.
This review article also addressed the pharmacokinetics
of representative anti-cancer agents, carboplatin, 5-FU,
and tyrosine kinase inhibitors. Although the optimal
interval between dialysis sessions and carboplatin infu-
sion has not been fully investigated, the usefulness of the
administration of carboplatin to HD patients has been
documented in previous reports, in which the dose was
calculated by the Calvert formula, assuming the GFR to
be zero. While the dose reduction of 5-FU may not be
recommended in previous studies, the metabolites of 5-
FU such as ammonia, fluoroacetate, and FBAL can be
accumulated in HD patients, indicating the need for the
reassessment of the optimal dose of 5-FU in HD pa-
tients. Although treatment with tyrosine kinase inhibi-
tors at the same dose as in normal subjects is often
feasible in HD patients, it should be kept in mind that
HD patients might be more susceptible to adverse effects
due to underlying risk factors. The data are limited,
mostly consisting of single case studies that have exam-
ined different chemotherapy protocols. Future studies
employing the same regimen for larger patient popula-
tions are warranted. The accumulation of studies will
lead to the establishment of optimal therapeutic strat-
egies for patients suffering from cancer and kidney
disease.
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